Hepatic steatosis is defined as pathologically elevated liver fat content and has many
underlying causes. Nonalcoholic fatty liver disease (NAFLD) is the most common chronic …

Nonalcoholic fatty liver disease (NAFLD) is estimated to afflict approximately 1 billion
individuals worldwide. In a subset of NAFLD patients, who have the progressive form of …

Alcohol-associated liver disease (ALD) represents a spectrum of liver injury resulting from
alcohol use, ranging from hepatic steatosis to more advanced forms including alcoholic …

This guidance provides a data‐supported approach to the diagnostic, therapeutic, and
preventive aspects of nonalcoholic fatty liver disease (NAFLD) care. A “Guidance” document …

Inhibition of apoptosis signal–regulating kinase 1, a serine/threonine kinase, leads to
improvement in inflammation and fibrosis in animal models of nonalcoholic steatohepatitis …

Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver
disease worldwide, and the progressive form of this condition, nonalcoholic steatohepatitis …

Importance Nonalcoholic fatty liver disease and its subtype nonalcoholic steatohepatitis
affect approximately 30% and 5%, respectively, of the US population. In patients with …

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease
in Western countries that is predicted to become also the most frequent indication for liver …

Nonalcoholic fatty liver disease (NAFLD) is a spectrum comprised of isolated steatosis,
nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. The majority of …

Obesity is a serious medical condition worldwide, which needs new approaches and
recognized international consensus in treating diseases leading to morbidity. The aim of this …